- 3PBIOVIAN has signed a contract with Colombia’s National Cancer Institute (INC) to develop a biosimilar monoclonal antibody for an oncology indication.
- The agreement covers full process development and technology transfer, with manufacturing planned at facilities in Colombia to support patient access.
3PBIOVIAN has signed a contract with the National Cancer Institute (Instituto Nacional de Cancerología, INC) in Colombia to develop a biosimilar monoclonal antibody (mAb) targeting an oncology indication. The project marks the first biosimilar mAb initiative aimed specifically at expanding access to oncology treatments in Colombia.
Under the agreement, the CDMO will conduct full process development activities. These include cell line development, process and analytical method development, process scale-up, and technology transfer to INC’s facilities in Colombia. Manufacturing of the biosimilar will ultimately take place in Colombia to supply product for patient care.
The collaboration also aligns with national efforts to strengthen Colombia’s biopharmaceutical capabilities. According to the announcement, the project supports initiatives to build local biomanufacturing capacity and reduce reliance on imported biologic medicines.
“We are proud to contribute to this project, which truly reflects 3PBIOVIAN’s purpose: to enable global access to high-quality biopharmaceuticals.”
Dámaso Molero, Group CEO of 3PBIOVIAN
The companies said the initiative is intended to improve access to affordable biologic therapies for oncology patients in Colombia while advancing the country’s efforts to develop domestic biotechnology and biologics manufacturing capacity.
